The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | ARUKA inhibition with VIC-1911 potentiates KRASG12Ci and overcomes resistance: what’s next?
Jong Woo Lee, MD, PhD, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, discusses the next steps following the finidngs that Aurora A kinase (ARUKA) inhibition with VIC-1911 potentiates KRASG12C inhibitors and overcomes resistance. A Phase I clinical trial testing VIC-1911 in combination with the KRASG12C inhibitor, sotorasib, in patients with lung cancer is soon to commence. Additionally, a cell line resistant to sotorasib has been established as well as genetically engineered mouse models with p53 knockout to investigate this combination. ARUKA will be further explored using patient samples from the Phase I clinical trial. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
